|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Herpesvirus 7 Antibodies (IgG, IgM)
Test Code10937
CPT Codes
86790 (x2)
Preferred Specimen
1 mL serum collected in a red-top tube (no gel)
Minimum Volume
0.5 mL
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly hemolyzed • Lipemic • Icteric samples
Methodology
Immunofluorescence Assay (IFA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Thurs; Report available: 1-7 days
Reference Range
Herpesvirus 7 Ab (IgG) | <1:320 titer |
<1:320 | No Increase in HHV-7 IgG titer |
1:320 | Equivocal |
>1:320 | Increased HHV-7 IgG titer |
Herpesvirus 7 Ab (IgM) | <1:20 titer |
<1:20 | Antibody Not Detected |
≥1:20 | Antibody Detected |
Clinical Significance
Human Herpesvirus 7 (HHV-7), a close relative of HHV-6, is found in >85% of the population, with transmission occurring in early childhood. Like HHV-6, HHV-7 is a cause of exanthum subitum (roseola infantum). Due to the ubiquitous nature of HHV-7 infection, >80% of individuals in the general population exhibit HHV-7 IgG titers ≥1:20; however, only 5% of these individuals exhibit titers >1:320. Thus, HHV-7 IgG titers >1:320 are suggestive of recent HHV-7 infection. Detection of HHV-7 specific IgM is also indicative of recent infection.